SINO BIOPHARMACEUT HKD0.025 (NASDAQ:SBMFF) has been given a consensus broker rating score of 4.00 (Sell) from the one brokers that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a sell recommendation.

Zacks has also assigned SINO BIOPHARMACEUT HKD0.025 an industry rank of 99 out of 265 based on the ratings given to its competitors.

Separately, Zacks Investment Research upgraded shares of SINO BIOPHARMACEUT HKD0.025 from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a research note on Thursday, August 10th.

Shares of SINO BIOPHARMACEUT HKD0.025 (NASDAQ SBMFF) traded up 3.4943% during midday trading on Tuesday, hitting $0.9004. The company had a trading volume of 250 shares. The company has a market capitalization of $6.67 billion and a price-to-earnings ratio of 23.6947. SINO BIOPHARMACEUT HKD0.025 has a 12-month low of $0.63 and a 12-month high of $0.93. The company’s 50-day moving average price is $0.87 and its 200 day moving average price is $0.81.

WARNING: “SINO BIOPHARMACEUT HKD0.025 (SBMFF) Receives Consensus Recommendation of “Sell” from Brokerages” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at

Get a free copy of the Zacks research report on SINO BIOPHARMACEUT HKD0.025 (SBMFF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Stock Ratings for SINO BIOPHARMACEUT HKD0.025 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SINO BIOPHARMACEUT HKD0.025 and related stocks with our FREE daily email newsletter.